Paolo Augusto Paoletti
Director/Board Member bei GENMAB A/S
Vermögen: 631 863 $ am 31.03.2024
Profil
Paolo Augusto Paoletti is currently serving as an Independent Director at Genmab A since 2015.
He is also a Director at Biomed Ltd., a Non-Executive Director at Akamis Bio Ltd., and a Director at Grid Therapeutics LLC.
In his former positions, Dr. Paoletti served as the Chairman & Chief Executive Officer at Kesios Therapeutics Ltd.
from 2015 to 2017.
He was also the Chief Executive Officer & Director at Gammadelta Therapeutics Ltd.
and a Director at FORMA Therapeutics, Inc. Additionally, he held the role of Independent Non-Executive Director at Forma Therapeutics Holdings, Inc. from 2015 to 2021.
Dr. Paoletti was a Non-Executive Director at NuCana Plc and Vice President-Oncology Research at Eli Lilly & Co. He also served as the President-Oncology Division at GSK Plc from 2013 to 2015 and as Vice President-Clinical Development at Lilly Oncology.
Dr. Paoletti obtained a doctorate degree from the University of Pisa.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GENMAB A/S
0,00% | 14.02.2024 | 2 090 ( 0,00% ) | 631 863 $ | 31.03.2024 |
Aktive Positionen von Paolo Augusto Paoletti
| Unternehmen | Position | Beginn |
|---|---|---|
| GENMAB A/S | Director/Board Member | 01.01.2015 |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Director/Board Member | - |
Biomed Ltd.
 Biomed Ltd. Pharmaceuticals: MajorHealth Technology Biomed Ltd. manufactures pharmaceutical products. The company is headquartered in Auckland, New Zealand. | Director/Board Member | - |
Grid Therapeutics LLC
 Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | Director/Board Member | - |
Ehemalige bekannte Positionen von Paolo Augusto Paoletti
| Unternehmen | Position | Ende |
|---|---|---|
| FORMA THERAPEUTICS HOLDINGS, INC. | Director/Board Member | 17.06.2021 |
Kesios Therapeutics Ltd.
 Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 01.01.2017 |
| GSK PLC | Corporate Officer/Principal | 01.04.2015 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Chief Executive Officer | - |
Ausbildung von Paolo Augusto Paoletti
| University of Pisa | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| GSK PLC | Health Technology |
| GENMAB A/S | Health Technology |
| NUCANA PLC | Health Technology |
| Private Unternehmen | 8 |
|---|---|
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
Forma Therapeutics Holdings, Inc.
 Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |
Biomed Ltd.
Biomed Ltd. Pharmaceuticals: MajorHealth Technology Biomed Ltd. manufactures pharmaceutical products. The company is headquartered in Auckland, New Zealand. | Health Technology |
Lilly Oncology
 Lilly Oncology Hospital/Nursing ManagementHealth Services Part of Eli Lilly & Co., Lilly Oncology is an American company dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. With over 50 years of experience, Lilly Oncology is committed to building on their heritage and improving the lives of all those affected by cancer worldwide. | Health Services |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Kesios Therapeutics Ltd.
Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Grid Therapeutics LLC
Grid Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Grid Therapeutics LLC develops and research cancer therapeutics to develop human derived antibodies. Its pipeline drugs include GT103 recombinant complement factor H monoclonal antibody and GT-20(x) recombinant monoclonal antibody. The company was founded by Edward F. Patz, Jr., Michael John Campagna and Elizabeth B. Gottlin and is headquartered in Chapel Hill, NC. | Commercial Services |
